Myeloid disease: Edited by Martin S. TallmanUmbilical cord blood transplantation for acute myeloid leukemiaAdvani, Anjali Sa; Laughlin, Mary JbAuthor Information aThe Cleveland Clinic Lerner College of Medicine, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, USA bDonald J. and Ruth Weber Goodman Professor of Innovative Cancer Therapeutics, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio, USA Correspondence to Anjali S. Advani, MD, Assistant Professor, The Cleveland Clinic, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA Tel: +1 216 445 9354; e-mail: [email protected] Current Opinion in Hematology: March 2009 - Volume 16 - Issue 2 - p 124-128 doi: 10.1097/MOH.0b013e3283257a60 Buy Metrics Abstract Purpose of review To discuss the recent advances in the field of umbilical cord blood (UCB) transplant (UCBT) for the treatment of adult acute myeloid leukemia. This topic is particularly relevant given the increasing use of UCBT and the plethora of clinical and biological studies being done to further optimize UCBT. Recent findings We will focus on clinical outcomes, results of nonmyeloablative UCBT, graft-versus-leukemia effect and graft-versus-host disease, the effects of UCBT on the immune system, and the role of multiple UCBTs and ex-vivo expansion. Summary Ultimately, these findings and research will allow us to expand UCB to a larger number of patients. In addition, a better understanding of the biology of UCB and subsequent manipulation of UCB and the immune system will allow us to improve the graft-versus-leukemia effect, improve engraftment, and decrease infectious complications after transplant. © 2009 Lippincott Williams & Wilkins, Inc.